INTRODUCTION
============

Although type 2 diabetes mellitus (T2DM), a prevalent and complex disease, is known to be caused by combinations of genes and environmental factors, the genetic contribution is not clearly evaluated. Dozens of single nucleotide polymorphisms (SNPs) in association with T2DM were identified by genome-wide association studies (GWAS), such as *PPAR, KCNJ11, TCF7L2, CDKAL1, CDKN2A/B,* and *FTO* ([@B1][@B2]). However, contribution of SNPs to development of T2DM was found to be limited, with reported estimates of genetic contribution to heritability for T2DM unveiled by GWAS as 6%-15% ([@B3][@B4]).

Genetic predisposition, expressed in scores of combined risk alleles of SNPs discovered from GWAS, has been used in researches on utilizing genotype information for practical use. One of them is constructing risk prediction models ([@B5][@B6][@B7]), which so far have shown limited improvement in prediction ability on T2DM risk, compared to common risk factors ([@B3][@B8]).

While limited explanation ability by SNPs on T2DM still remains as a challenge, possibility of disparity in predictive performance by study design and population characteristics has been pointed out ([@B9]). As most of the polygenic T2DM prediction studies are based on Caucasian populations, extending the research to non-European subjects has been strongly recommended ([@B10]).

Therefore, we aimed to explore the contribution of genetic variants on T2DM in a different ethnicity using a well-designed prospective data from a community-based cohort study in Korea. With SNPs found to be in association with T2DM from previously reported studies, we made a genetic predisposition score (GPS) in constructing the prediction models in a cohort study of 8-yr follow-up.

MATERIALS AND METHODS
=====================

The Anseong-Ansan Cohort Study, one of the 3 prospective community- based cohort studies from the Korean Genome and Epidemiology Study (KoGES), begun with 10,038 subjects aged 40 to 69 yr at baseline (2001-2003). Whole-genome sequencing using Affymetrix 500K Array (Affymetrix, Santa Clara, CA, USA) was performed in 8,842 randomly selected subjects during the baseline investigation period, and unphased genotypes were imputed with Japanese+Chineses HapMap phase 2 haplotype panel using IMPUTE version 2 (<http://mathgen.stats.ox.ac.uk/impute>). Follow-up studies are carried out in 2-yr intervals, at 2003-2005, 2005-2007, and so on. In this study, we used 8-yr follow-up data, collected biennially until the 4th follow-up (2009-2011). Details regarding the KoGES, including methods and quality control for the genotyping, have been described in previous reports ([@B11][@B12]).

At baseline, we excluded 2 subjects without any information needed for T2DM definition, 683 subjects with history of DM diagnosis/treatment or in current oral hypoglycemic medication/insulin therapy for DM, and 544 subjects with glycated hemoglobin (HbA1c) ≥6.5% or fasting plasma glucose (FPG)≥7.0 mM/L or plasma glucose level 2-hr after ingestion of 75 g oral glucose load (2 hr-OGTT) ≥11.1 mM/L. From 8,809 subjects at baseline, 954 (10.8%) subjects were eliminated due to follow-up loss after fourth follow-up in 2009-2011. Of the remaining 7,855 subjects, we excluded another 945 (12.0%) subjects who had not been selected for genotyping procedures at baseline. Thus 6,910 subjects remained for analysis ([Fig. 1](#F1){ref-type="fig"}). Incident T2DM cases at each follow-up was identified as corresponding to at least one of the following definitions: HbA1c ≥6.5%, FPG ≥7.0 mM/L, 2 hr-OGTT ≥11.1 mM/L, or in treatment state for T2DM with insulin or oral hypoglycemic medication since the last follow-up or two years\' period.

In our study, we tested 38 SNPs reported to be in association with T2DM in Korean or East Asian population, from GWAS meta-analysis or candidate gene analysis that partly or entirely used KoGES baseline data ([@B11][@B13][@B14]). We investigated frequency of risk alleles of each SNP, and calculated hazard ratios (HR) and 95% confidence intervals (CI) by the risk allele on the incident T2DM in our study subjects by Cox\'s proportional hazard functions. For GPS, numbers of risk alleles of selected SNPs were combined to a continuous variable, ranging from 0 to number of selected SNPs multiplied by 2. We also calculated weighted GPSs to adjust for different effect estimates of each SNP in association with T2DM, using relative effect sizes from the association analysis. Thus, higher GPS indicate a higher genetic predisposition to T2DM ([@B15]).

Statistical analysis
--------------------

Cox\'s proportional hazard functions were used to estimate HR and their 95% CIs. Stepwise procedures were used for variable selection in the prediction model. First, we tested all a priori covariates in a univariate Cox regression model at significant level of *P* value≤0.2, then fitted all significant and non-significant covariates in multivariate Cox regression models with *P* value≤0.15 required for inclusion in backward and forward selection procedures, respectively. Finally, we used stepwise selection with the selected covariates with *P* value≤0.15 to attain the main-effects model. Likelihood ratio test was used for all covariate inclusion/exclusion decisions ([@B16]).

From the full model with all selected variables, we also constructed several subset models in accordance with previous literature ([@B5][@B17]). For all subset models, we evaluated discrimination, calibration and risk reclassification after adding risk alleles (i.e. GPS) in the models. C-statistics and Hosmer-Lemeshow chi-square test were used to test for model discrimination and calibration, and net reclassification index (NRI) and integrated discrimination improvement (IDI) were analyzed to examine risk reclassification upon addition of selected risk alleles ([@B18]).

A two-tailed *P*\<0.05 indicated statistical significance. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA) and Stata/SE 13.0 (StataCorp LP, College Station, TX, USA).

Ethics statement
----------------

Informed written consent was obtained from all participants, and the study protocol was approved by the institutional review board of the Korea Centers for Disease Control and Prevention (KCDC) as well as Seoul National University Hospital (IRB No. 1306-046-495).

RESULTS
=======

Mean age of subjects were 51.8 yr at baseline, and males accounted for 47% of the total 6,910 subjects. Over the 8-yr follow-up, 1,240 (18.0%) were defined as incident T2DM cases ([Table 1](#T1){ref-type="table"}). As well as variables tested for prediction modeling (i.e. age, body mass index \[BMI\], triglyceride \[TG\], FPG, HbA1C, etc.) GPSs were higher in incident diabetic cases compared to those who remained non-diabetic (*P* value\<0.001).

Among the selected 38 SNPs, three SNPs, rs10811661 (*CDKN2A/B*), rs5215 (*KCNJ11*), and rs2237892 (*KCNQ1*) showed significant association with T2DM incidence in our subjects (rs10811661, HR 1.22 \[95% CI 1.02-1.46\]; rs5215, HR 1.27 \[1.06-1.52\], rs2237892, HR 1.37 \[1.12-1.68\]), and most SNPs showed same direction of estimate as reported by original researches ([Table 2](#T2){ref-type="table"}). In constructing GPS, we eliminated rs7756992 and rs71724 32 as they showed strong linkage with rs9465871 (D\'=0.977, r^2^=0.933) and rs1436955 (D\'=1, r^2^=0.627), respectively. We constructed three GPSs with differently selected SNPs, i.e. 1) GPS-3 with three SNPs in significant association with T2DM in our study subjects (range 0-6); 2) GPS-18 with 18 SNPs analyzed by Affymetrix 500K (range 0-36); 3) GPS-36, with addition of 18 further SNPs attained through imputation of HapMap data (range 0-72).

After stepwise selection procedures, age, BMI, family history of T2DM, hypertension history, regular physical exercise, and clinical indices such as triglyceride, FPG, and HbA1c as well as GPSs were selected as variables for risk prediction modeling. We used subsets of variables in building simple (information from questionnaires and anthropometric measurements, i.e. age, BMI, family history of T2DM, history of hypertension, regular physical excercise), clinical (variables from simple model plus clinical examination data, i.e. serum TG, HDL-cholesterol, FPG levels), and full clinical (variables from clinical model plus serum HbA1c level) models. Within the models, we tested for significant changes in discrimination and reclassification by the prediction models upon addition of GPS-3 ([Table 3](#T3){ref-type="table"}), GPS-18 ([Table 4](#T4){ref-type="table"}) or GPS-36 ([Table 5](#T5){ref-type="table"}).

Hazard ratios for T2DM incidence per risk allele score increase were 1.11 (95% CI 1.06-1.17, full clinical model), 1.03 (1.01-1.06), and 1.04 (1.02-1.07), in cases of GPS-3, GPS-18, and GPS-36, respectively. This relationship was significant across all three models, and HRs analyzed with weighted GPSs also showed significant results (1.11; 95% CI, 1.06-1.17, full clinical model), 1.03 (1.01-1.05), and 1.04 (1.01-1.05) with GPS-3, GPS-18, GPS-36, respectively).

Evaluation of risk prediction in addition to GPSs is also shown in [Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}. In case of comparing prediction models with or without GPS-3 ([Table 3](#T3){ref-type="table"}), subtle significant changes in area under the curve (ΔAUC) were found across all three models (ΔAUC; 0.007 \[*P*=0.044\], 0.005 \[*P*=0.007\], 0.003 \[*P*=0.024\] for simple, clinical, full clinical models, respectively), while reclassification analysis showed significance with simple and clinical models but not with full clinical model, where HbA1c is lastly added (NRI; 6.1% \[*P*\<0.001\], 3.1% \[*P*=0.006\], 2.0% \[*P*=0.106\], respectively). In case of GPS-18 ([Table 4](#T4){ref-type="table"}), both discrimination (ΔAUC; 0.007 \[*P*=0.033\], 0.003 \[*P*=0.054\], 0.001 \[*P*=0.130\] for simple, clinical, full clinical models, respectively) and reclassification (NRI; 5.1% \[*P*\<0.001\], 3.3% \[*P*=0.002\], 1.0% \[*P*=0.336\], respectively) indices were significant or borderline-significant at simple but not in full clinical models. In case of GPS-36 ([Table 5](#T5){ref-type="table"}), significant or borderline-significant discrimination was observed (ΔAUC; 0.014 \[*P*=0.047\], 0.006 \[*P*=0.041\], 0.005 \[*P*=0.050\] for simple, clinical, full clinical models, respectively). Similar to reclassification improvement with GPS-3 and GPS-18, NRI was positively significant in simple and clinical models, but not in full clinical model (NRI; 8.6% \[*P*\<0.001\], 4.4% \[*P*=0.012\], 1.7% \[*P*=0.352\], respectively).

DISCUSSION
==========

From a community cohort of 8-yr follow-up in Korea, we observed some influence of genetic predisposition drawn from genotype information on 3, 18, and 36 selected SNPs, on risk of T2DM incidence. The significant discrimination or reclassification indices upon addition of GPS in simple and clinical models were on longer observed in full models, i.e. when HbA1c was finally included, and this tendency was consistent across all three tested GPSs.

Risk prediction modeling for T2DM on the same Anseong-Ansan cohort population had been carried out previously, at 4-yr follow-up and without considering for genetic predisposition. The authors also had focused on the HbA1c variable, which substantially increased NRI (12.8%) upon addition to the prediction model ([@B12]). Another 5-yr follow-up cohort study on Japanese population also reported FPG and HbA1c together were effective predictors for T2DM incidence ([@B19]). Lastly, a case-cohort research from European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study that utilized metabolic markers including HbA1c as well as genetic markers in predicting T2DM risk, found that addition of genetic information to metabolic markers, age, anthropometry, and lifestyle characteristics, did not significantly improve disease prediction, while FPG and HbA1c considerably contributed to the prediction ([@B20]). Thus, as an indicator of chronic glycemia, it is convincible that HbA1c is a strong indicator of T2DM prediction, well over information on genetic predisposition ([@B21]). Our results, where the apparent influence by genetic variation on T2DM prediction weakened in the final model including HbA1c, strongly support the previous findings. At the same time, the decrease in prediction ability across the simple, clinical and full clinical models also imply that HbA1c is a phenotype already inherent and reflected by the genetic predisposition, as confirmed by significant association between the selected SNPs and HbA1c levels in our subjects ([Supplementary Table 2](#S2){ref-type="supplementary-material"}). To our knowledge, ours is one of the few studies that utilized information on both genetic predisposition and HbA1c in testing T2DM risk prediction model, especially in a non-European ethnicity.

As younger populations are subject to less developed clinical risk factors, confirming our findings in a younger population would be meaningful. In younger adults, HbA1c may be a less important factor in predicting T2DM, and influence by genetic variation may persist even after multiple-variable adjustment ([@B17]). However, inconsistent and non-significant results were found in subjects ≤50 yr old in our study (results not shown). This may be explained by poor validity due to much decreased number and the baseline characteristic of the middle-aged participants, who may have already begun developing subclinical metabolic disorders.

We have selected SNPs already validated from previous studies that included genetic information from the same Anseong-Ansan cohort for GWAS or meta-GWAS analyses. Also, the association tests between the SNPs and T2DM incidence (or prevalence) were restricted to East Asian populations. This method has advantage over a single GWAS in the study population, which face insufficient validity of results due to small number of subjects and limited resource for independent population with identical ethnicity for replication. On the other hand, the major disadvantage of this method is possibility of overfitting. The significant SNPs found in our study, already replicated in studies including the same subjects, could otherwise be interpreted as those that show strong association specifically in our Anseong-Ansan cohort subjects. Again, this problem could be overcome by replication in an independent population of identical ethnicity. The pros and cons of using validated SNPs for which information from same subjects were utilized as subset data warrant further investigation.

Three SNPs with significant HRs found in our study were *KCNJ11* (rs5215), *CDKN2A/B* (rs10811661), and *KCNQ1* (rs22378 92), and their HRs were about 1.3. Insulin secretion is the main explained function of the three genes, with *CDKN2A/1B* in relation with development of pancreatic β-cells, while *KCNJ11* and *KCNQ1* are related with the β-cell dysfunction ([@B22]), and effects of these genotype variants on T2DM have been tested in East Asian populations ([@B11][@B23][@B24]). *KCNJ11* (potassium inwardly-rectifying channel, subfamily J, member 11) regulates glucose-dependent insulin secretion, and its mutations have been reported to cause severe neonatal diabetes ([@B25]). It consists a subunit of sulfonylurea receptor, and the mutation can alter response to sulfonylurea treatment in T2DM patients ([@B26]). *CDKN2A/B* (cyclin-dependent kinase inhibitor 2A/B) and *KCNQ1* (potassium voltage-gated channel, KQT-like subfamily, member 1) are known to be associated with impaired pancreatic β-cell function ([@B22]). Mutation in rs10811661 is also known for its association with myocardial infarction, to which T2DM is a high risk factor ([@B27]).

In the prediction models that included GPSs, we found independent effects of family history of T2DM and GPS on T2DM risk, with greater HRs by family history than GPS across all subset models with all three GPSs. Our results support speculations that family history may provide more information from shared environmental influence, i.e. non-genetic familial behaviors such as lifestyle and dietary habits, than inherited genetic influence alone ([@B5][@B6]). Thus, while considering family history of T2DM is necessary in investigating genetic influence by the risk alleles, we also suggest research on gene-environment interactions and epigenetics to be continuously encouraged ([@B3][@B28]).

Although we constructed risk prediction models from a prospective cohort study, duration of follow-up was relatively short. Longer follow-up duration could improve prediction ability of genetic variants relative to time-varying factors e.g. clinical examination findings, as discrimination power of GPS increase with extended follow-up period ([@B7][@B10]). Also, we could not consider lifestyle risk factors such as smoking and diet in our prediction model due to statistical insignificance of their influence on T2DM and subsequent elimination by statistical procedures, despite the alleged influence to the disease ([@B29]). As studies have also reported some interaction effect between behavioral risk factors and genetic polymorphisms as well as significant effect of lifestyle intervention in subjects with high genetic risk scores ([@B30]), further investigations on gene-lifestyle interaction may be required.

In conclusion, we observed influence of genetic variation, described by subsets of selected SNPs, on risk prediction of T2DM incidence in a 8-yr cohort of middle-aged Koreans, but the significance in discrimination and reclassification of prediction ability disappeared when information on HbA1c levels were added. We have also verified three SNPs in significant association with T2DM in our subjects, and our results as elementary findings may contribute to expanded genetic studies.
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Supplementary Material
======================

###### Evaluation of T2DM risk prediction with consideration for age and genetic predisposition derived from selected SNPs (GPS-3, GPS-18, GPS-36)

![](jkms-30-1101-s001)

                                Without GPS-3         With GPS-3            Without GPS-18        With GPS-18           Without GPS-36        With GPS-36
  ----------------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------
  Age                           1.03 (1.02-1.03)      1.03 (1.02-1.03)      1.03 (1.02-1.03)      1.03 (1.02-1.03)      1.03 (1.02-1.04)      1.03 (1.02-1.04)
  GPS                                                 1.13 (1.07-1.19)                            1.05 (1.02-1.08)                            1.06 (1.03-1.08)
  *GPS* (*weighted*)                                  *1.14 (1.06-1.17)*                          *1.04 (1.02-1.06)*                          *1.04 (1.02-1.06)*
  \(1\) Discrimination                                                                                                                        
   AUC (95% CI)                 0.566 (0.547-0.584)   0.577 (0.559-0.596)   0.567 (0.549-0.585)   0.574 (0.556-0.593)   0.578 (0.551-0.604)   0.594 (0.567-0.62)
   *P* value for contrast       0.031                 0.120                 0.058                                                             
  \(2\) Calibration                                                                                                                           
   Hosmer-Lemeshow χ^2^ (*P*)   9.97 (0.267)          15.38 (0.0522)        9.07 (0.3368)         6.94 (0.5426)         14.34 (0.0733)        10.06 (0.2609)
  \(3\) Reclassification                                                                                                                      
   IDI, (SE)                    0.0030 (0.0007)       0.0029 (0.0007)       0.0064 (0.0015)                                                   
   *P* value                    \<0.001               \<0.001               \<0.001                                                           
   NRI                          NA                    NA                    NA                                                                

NA, not available due to conformability error.

###### Effect of genetic predisposition on (a) baseline HbA1c or (b) change of HbA1c

![](jkms-30-1101-s002)

                                 \(a\) Regression analysis   \(b\) Mixed model analysis                     
  ------------ ----------------- --------------------------- ---------------------------- ----------------- ----------
  rs10811661   Crude             0.0117 (0.006)              0.049                        0.0219 (0.0069)   0.002
  Adjusted     0.0103 (0.006)    0.089                       0.0102 (0.0059)              0.082             
  rs5215       Crude             0.0083 (0.0061)             0.178                        0.0086 (0.0071)   0.023
  Adjusted     0.0112 (0.0062)   0.070                       0.0137 (0.006)               0.024             
  rs2237892    Crude             0.0152 (0.0064)             0.018                        0.0252 (0.0074)   \< 0.001
  Adjusted     0.0143 (0.0064)   0.025                       0.017 (0.0063)               0.007             
  GPS-3        Crude             0.0123 (0.0037)             \< 0.001                     0.0202 (0.0043)   \< 0.001
  Adjusted     0.012 (0.0037)    0.001                       0.014 (0.0036)               \< 0.001          
  GPS-18       Crude             0.0078 (0.0016)             \< 0.001                     0.0105 (0.0019)   \< 0.001
  Adjusted     0.0074 (0.0017)   \< 0.001                    0.0079 (0.0016)              \< 0.001          
  GPS-36       Crude             0.0103 (0.0018)             \< 0.001                     0.0144 (0.0021)   \< 0.001
  Adjusted     0.0077 (0.0018)   \< 0.001                    0.0081 (0.0018)              \< 0.001          

Adjusted for age, BMI, hypertension history, family history of T2DM, regular physical activity, and serum levels of TG, HDL-cholesterol, FPG.

![Flow chart showing selection of subjects included in the analysis.](jkms-30-1101-g001){#F1}

###### Baseline characteristics of study subjects

![](jkms-30-1101-i001)

  Parameters                                                 All (n = 6,910)   Case (n = 1,240)   Control (n = 5,670)
  ------------------------------------------ --------------- ----------------- ------------------ ---------------------
  Mean ± SD                                                                                       
   Age (yr)                                                  51.77 ± 8.79      53.4 ± 8.78        51.41 ± 8.76
   Body mass index (kg/m^3^)                                 24.47 ± 3.02      25.04 ± 3.21       24.34 ± 2.96
   HDL cholesterol (mM/L)                                    1.17 ± 0.26       1.13 ± 0.26        1.17 ± 0.26
   Triglyceride (mM/L)                                       1.76 ± 1.10       2.09 ± 1.29        1.69 ± 1.04
   Fasting glucose (mM/L)                                    4.61 ± 0.50       4.88 ± 0.61        4.56 ± 0.45
   HbA1c (%)                                                 5.55 ± 0.35       5.77 ± 0.36        5.51 ± 0.33
   Risk allele scores of 3 analyzed SNPs                     3.13 ± 1.19       3.27 ± 1.2         3.1 ± 1.18
   Risk allele scores of 18 analyzed SNPs                    18.76 ± 2.71      19.04 ± 2.73       18.69 ± 2.71
   Risk allele scores of 36 analyzed SNPs                    40.54 ± 3.53      41.07 ± 3.58       40.43 ± 3.51
   Average systolic blood pressure (mmHg)                    120.71 ± 18.17    125.04 ± 18.77     119.77 ± 17.9
   Average diastolic blood pressure (mmHg)                   79.98 ± 11.41     82.31 ± 11.48      79.47 ± 11.33
   Average waist circumference (cm)                          82.13 ± 8.68      84.16 ± 8.78       81.68 ± 8.6
   Average hip circumference (cm)                            93.47 ± 5.91      94.32 ± 5.98       93.29 ± 5.87
   HOMA-IR                                                   1.55 ± 1.00       1.70 ± 1.02        1.52 ± 0.99
  Frequency (%)                                                                                   
   Sex                                       Male            3,251 (47.05)     642 (51.77)        2,609 (46.01)
  Female                                     3,659 (52.95)   598 (48.23)       3,061 (53.99)      
   Current smoking                           No              5,124 (75.07)     893 (72.9)         4,231 (75.54)
  Yes                                        1,702 (24.93)   332 (27.1)        1,370 (24.46)      
   Current drinking                          No              3,561 (51.96)     618 (50.24)        2,943 (52.34)
  Yes                                        3,292 (48.04)   612 (49.76)       2,680 (47.66)      
   Regular physical activity                 No              2,842 (41.53)     465 (37.71)        2,377 (42.37)
  Yes                                        4,001 (58.47)   768 (62.29)       3,233 (57.63)      
   Family history of T2DM                    No              6,191 (89.59)     1,066 (85.97)      5,125 (90.39)
  Yes                                        719 (10.41)     174 (14.03)       545 (9.61)         
   Hypertension                              No              4,928 (71.32)     750 (60.48)        4,178 (73.69)
  Yes                                        1,982 (28.68)   490 (39.52)       1,492 (26.31)      
   Metabolic syndrome                        No              4,654 (67.35)     641 (51.69)        4,013 (70.78)
  Yes                                        2,256 (32.65)   599 (48.31)       1,657 (29.22)      

HDL, high-density lipoprotein; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance index; T2DM, type 2 diabetes mellitus.

###### Characteristics of selected risk loci for type 2 diabetes mellitus

![](jkms-30-1101-i002)

  SNP                                   Chromosomes   Locus             Risk allele   RAF of case/control   HR (95% CI)            *P* value   Reported OR (95% CI) in East Asians^\*^   Reported OR (95% CI) in Caucasians^†^
  ------------------------------------- ------------- ----------------- ------------- --------------------- ---------------------- ----------- ----------------------------------------- ---------------------------------------
  18 SNPs analyzed by Affymetrix 500K                                                                                                                                                    
   rs10923931                           1             *NOTCH2*          T             0.04/0.03             0.88 (0.12-6.24)       0.896       1.05 (0.92-1.20)                          1.13 (1.08-1.17) (1)
   rs7593730                            2             *RBMS1*           C             0.83/0.83             1.28 (0.86-1.91)       0.224       1.03 (0.97-1.09)                          1.11 (1.08-1.16) (2)
   rs1470579                            3             *IGF2BP2*         C             0.33/0.31             1.07 (0.86-1.34)       0.526       1.13 (1.08-1.19)                          1.17 (1.11-1.23) (3)
   rs1801282                            3             *PPARG*           C             0.96/0.95             1.83 (0.46-7.33)       0.394       1.13 (1.01-1.28)                          1.14 (1.08-1.20) (3)
   rs4607103                            3             *ADAMTS9*         C             0.62/0.61             1.11 (0.91-1.35)       0.317       0.99 (0.95-1.04)                          1.09 (1.06-1.12) (1)
   rs831571                             3             *PSMD6*           C             0.63/0.63             1 (0.83-1.21)          0.993       1.09 (1.06-1.12)                          NA
   rs7754840                            6             *CDKAL1*          C             0.48/0.47             1.15 (0.97-1.37)       0.114       1.20 (1.14-1.25)                          1.12 (1.08-1.16) (4)
   rs9465871                            6             *CDKAL1*          C             0.56/0.54             1.15 (0.97-1.38)       0.110       1.14 (1.09-1.18)                          NA
   rs864745                             7             *JAZF1*           T             0.74/0.72             1.27 (0.98-1.65)       0.074       1.06 (1.00-1.12)                          1.10 (1.07-1.13) (1)
   **rs10811661**                       9             ***CDKN2A/B***    **T**         0.58/0.56             **1.22 (1.02-1.46)**   0.033       1.21 (1.14-1.28)                          1.20 (1.14-1.25) (4)
   rs10906115                           10            *CDC123/CAMK1D*   A             0.54/0.53             1.06 (0.89-1.26)       0.528       1.09 (1.04-1.14)                          1.13 (1.08-1.18) (5)
   rs5015480                            10            *HHEX*            C             0.19/0.19             0.97 (0.69-1.36)       0.855       1.16 (1.1-1.23)                           1.19 (1.11-1.28) (6)
   **rs5215**                           11            ***KCNJ11***      **C**         0.41/0.39             **1.27 (1.06-1.52)**   0.010       1.13 (1.08-1.18)                          1.14 (1.10-1.19) (7)
   rs1531343                            12            *HMGA2*           C             0.11/0.11             0.77 (0.45-1.31)       0.335       1.06 (0.99-1.14)                          1.10 (1.07-1.14) (8)
   rs7961581                            12            *TSPAN8/LGR5*     C             0.22/0.23             0.84 (0.63-1.11)       0.207       1.01 (0.95-1.06)                          1.09 (1.06-1.12) (1)
   rs1359790                            13            *SPRY2*           G             0.71/0.7              1.17 (0.94-1.47)       0.166       1.02 (0.97-1.08)                          1.15 (1.10-1.20) (5)
   rs1436955                            15            *C2CD4A/C2CD4B*   C             0.7/0.69              0.94 (0.76-1.16)       0.583       1.13 (1.06-1.21)                          NA
   rs9939609                            16            *FTO*             A             0.87/0.88             1.09 (0.67-1.79)       0.726       1.15 (1.08-1.22)                          1.15 (1.09-1.23) (9)
  20 SNPs from HapMap imputation                                                                                                                                                         
   rs340874                             1             *PROX1*           C             0.37/0.35             1.16 (0.96-1.41)       0.132       1.08 (1.03-1.14)                          1.07 (1.05-1.09) (10)
   rs243021                             2             *BCL11A*          A             0.67/0.66             1.03 (0.84-1.27)       0.790       1.05 (1.00-1.10)                          1.08 (1.06-1.10) (8)
   rs2943641                            2             *IRS1*            C             0.94/0.95             0.44 (0.14-1.37)       0.155       1.12 (1.03-1.22)                          1.19 (1.13-1.25) (11)
   rs6780569                            3             *UBE2E2*          G             0.83/0.81             1.2 (0.83-1.76)        0.337       1.13 (1.07-1.20)                          1.21 (1.14-1.30) (12)
   rs10010131                           4             *WFS1*            G             0.98/0.98             NA                     0.947       1.00 (0.91-1.10)                          1.11 (1.05-1.16) (13)
   rs7756992                            6             *CDKAL1*          G             0.56/0.54             1.16 (0.97-1.39)       0.314       1.14 (1.09-1.18)                          1.19 (1.13-1.27) (14)
   rs2191349                            7             *DGKB*            T             0.68/0.68             1 (0.8-1.25)           0.978       1.11 (1.05-1.16)                          1.06 (1.04-1.08) (10)
   rs4607517                            7             *GCK*             A             0.23/0.21             1.21 (0.92-1.6)        0.173       1.03 (0.97-1.09)                          1.07 (1.05-1.10) (10)
   rs972283                             7             *KLF14*           G             0.7/0.69              1.17 (0.93-1.48)       0.186       0.99 (0.93-1.06)                          1.07 (1.05-1.10) (8)
   rs13266634                           8             *SLC30A8*         C             0.59/0.59             1.02 (0.84-1.22)       0.871       1.11 (1.06-1.16)                          1.15 (1.12-1.19) (15)
   rs896854                             8             *TP53INP1*        T             0.29/0.29             0.93 (0.72-1.19)       0.546       1.07 (1.02-1.12)                          1.06 (1.04-1.09) (8)
   rs13292136                           9             *CHCHD9*          C             0.9/0.89              0.88 (0.54-1.44)       0.610       0.99 (0.92-1.07)                          1.11 (1.07-1.15) (8)
   rs12779790                           10            *CDC123/CAMK1D*   G             0.11/0.1              1.27 (0.75-2.15)       0.381       1.12 (1.02-1.23)                          1.11 (1.07-1.14) (1)
   rs7903146                            10            *TCF7L2*          T             0.03/0.02             1.45 (0.21-10.24)      0.711       1.16 (1.02-1.31)                          1.37 (1.31-1.43) (4)
   rs10830963                           11            *MTNR1B*          G             0.44/0.44             0.98 (0.82-1.17)       0.816       0.99 (0.93-1.06)                          1.09 (1.06-1.12) (10)
   rs1552224                            11            *CENTD2*          A             0.94/0.94             1.04 (0.85-1.27)       0.143       1.16 (1.06-1.27)                          1.14 (1.11-1.17) (8)
   **rs2237892**                        11            ***KCNQ1***       **C**         0.64/0.6              **1.37 (1.12-1.68)**   0.003       1.17 (1.11-1.23)                          1.40 (1.34-1.47) (16)
   rs231362                             11            *KCNQ1*           G             0.89/0.88             1.17 (0.64-2.12)       0.623       1.10 (1.00-1.20)                          1.08 (1.06-1.10) (8)
   rs2334499                            11            *INS/IGF2B*       T             0.82/0.82             0.81 (0.6-1.09)        0.167       NA                                        1.35 (NA) (17)
   rs7172432                            15            *C2CD4A/C2CD4B*   A             0.55/0.55             1.02 (0.85-1.22)       0.989       1.09 (1.04\--1.15)                        1.14 (1.09-1.20) (12)

Adjusted for age, sex, and body mass index. ^\*^Referred from Cho YS et al. ([@B11]), 2012, Ryoo H et al. ([@B13]), 2011 and Shu XO et al. ([@B14]); ^†^References for reported odd ratios (OR) and CIs in Caucasians are in the Supplemental Material. HR, OR and CI, hazard ratio, odds ratio and confidence intervals; RAF, risk allele frequency; NA, not available.

###### Evaluation of T2DM risk prediction with consideration for genetic predisposition derived from 3 selected SNPs (GPS-3)

![](jkms-30-1101-i003)

  Risk factors                                          Model 1: Simple model   Model 3: Full clinical model   Model 3: Full clinical model                                               
  ---------------------------------- ------------------ ----------------------- ------------------------------ ------------------------------ --------------------- --------------------- ---------------------
  Age                                                   1.02 (1.02-1.03)        1.02 (1.02-1.03)               1.03 (1.02-1.03)               1.03 (1.02-1.03)      1.02 (1.01-1.03)      1.02 (1.01-1.03)
  BMI (Ref: \< 23 kg/m^3^)           23-25              1.16 (0.98-1.36)        1.16 (0.98-1.37)               1.07 (0.91-1.26)               1.07 (0.91-1.27)      1.07 (0.90-1.26)      1.07 (0.91-1.26)
  25-30                              1.41 (1.22-1.62)   1.43 (1.24-1.64)        1.17 (1.01-1.35)               1.18 (1.02-1.36)               1.11 (0.96-1.29)      1.12 (0.97-1.30)      
  ≥ 30                               1.87 (1.42-2.45)   1.91 (1.46-2.51)        1.58 (1.20-2.07)               1.62 (1.23-2.13)               1.42 (1.08-1.87)      1.45 (1.10-1.91)      
  Family history of T2DM (Ref: No)   Yes                1.57 (1.32-1.87)        1.55 (1.30-1.85)               1.41 (1.18-1.68)               1.39 (1.17-1.66)      1.36 (1.14-1.62)      1.35 (1.13-1.61)
  HTN history (Ref: No)              Yes                1.44 (1.27-1.64)        1.44 (1.27-1.64)               1.17 (1.03-1.34)               1.18 (1.03-1.34)      1.18 (1.03-1.34)      1.18 (1.03-1.34)
  Regular exercise (Ref: No)         Yes                1.28 (1.13-1.45)        1.29 (1.13-1.46)               1.25 (1.10-1.42)               1.25 (1.10-1.43)      1.27 (1.12-1.44)      1.27 (1.12-1.45)
  Triglyceride (Ref: \< 120 mg/dL)   120-150                                                                   1.26 (1.05-1.52)               1.26 (1.05-1.52)      1.24 (1.03-1.49)      1.24 (1.03-1.49)
  ≥ 150                                                                         1.84 (1.58-2.14)               1.85 (1.59-2.15)               1.74 (1.49-2.02)      1.75 (1.50-2.03)      
  HDL-C (Ref: ≥ 50 mg/dL)            \< 35                                                                     1.32 (1.07-1.62)               1.32 (1.07-1.62)      1.32 (1.07-1.62)      1.31 (1.07-1.61)
  35-49                                                                         1.10 (0.94-1.28)               1.10 (0.95-1.28)               1.11 (0.95-1.29)      1.11 (0.95-1.30)      
  FPG (Ref: 90-100 mg/dL)            \< 90                                                                     0.51 (0.44-0.59)               0.51 (0.44-0.60)      0.54 (0.47-0.63)      0.55 (0.47-0.63)
  ≥ 100                                                                         2.47 (2.02-3.01)               2.48 (2.03-3.02)               2.34 (1.92-2.85)      2.35 (1.93-2.87)      
  HbA1c (Ref: \< 5.5%)               ≥ 5.5                                                                                                                          1.97 (1.69-2.29)      1.96 (1.69-2.28)
  GPS-3                                                                         1.12 (1.07-1.18)                                              1.11 (1.06-1.17)                            1.11 (1.06-1.17)
  *GPS-3*(*weighted*)                                                           *1.09 (1.05-1.14)*                                            *1.09 (1.05-1.13)*                          *1.11 (1.06-1.17)*
  1\) Discrimination                                                                                                                                                                      
   AUC (95% CI)                                         0.624 (0.606-0.642)     0.631 (0.613-0.649)            0.703 (0.685-0.720)            0.708 (0.690-0.725)   0.723 (0.705-0.740)   0.726 (0.709-0.743)
   *P* value for contrast                               0.044                   0.007                          0.024                                                                      
  2\) Calibration                                                                                                                                                                         
   Hosmer-Lemeshow χ^2^ (*P*)                           4.72 (0.7866)           10.50 (0.2318)                 8.51 (0.3851)                  10.08 (0.2594)        11.73 (0.1636)        5.44 (0.7092)
  3\) Reclassification                                                                                                                                                                    
   IDI, (SE)                                            0.0034 (0.0008)         0.0027 (0.0009)                0.0026 (0.0009)                                                            
   *P* value                                            \< 0.001                0.002                          0.002                                                                      
   NRI, (SE)                                            0.0610 (0.0145)         0.0309 (0.0113)                0.0196 (0.0122)                                                            
   *P* value                                            \< 0.001                0.006                          0.106                                                                      

Range of risk alleles scores (GPS-3); 0-6. Model 1 (simple model) adjusted for age, BMI, family history of T2DM, HTN history, regular physical exercise±risk alleles; model 2 (clinical model), adjusted for variables in model 1 plus triglyceride, HDL-cholesterol, FPG±risk alleles; model 3, adjusted for all variables in model 3±risk alleles. Risk classification in NRI analysis: 10%, 20%, 30%. T2DM, type 2 diabetes mellitus; GPS, genetic predisposition score; HDL, high-density lipoprotein; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance index; AUC, area under the curve; IDI, integrated discrimination improvement; NRI, net reclassification improvement.

###### Evaluation of T2DM risk prediction with consideration for genetic predisposition derived from 18 selected SNPs (GPS-18)

![](jkms-30-1101-i004)

  Parameters                                            Model 1: Simple model   Model 2: Clinical model   Model 3: Full clinical model                                               
  ---------------------------------- ------------------ ----------------------- ------------------------- ------------------------------ --------------------- --------------------- ---------------------
  Age                                                   1.02 (1.02-1.03)        1.02 (1.02-1.03)          1.02 (1.02-1.03)               1.02 (1.02-1.03)      1.02 (1.01-1.03)      1.02 (1.01-1.03)
  BMI (Ref: \< 23 kg/m^3^)           23-25              1.13 (0.96-1.33)        1.13 (0.96-1.33)          1.05 (0.89-1.23)               1.05 (0.89-1.24)      1.05 (0.89-1.24)      1.05 (0.89-1.24)
  25-30                              1.40 (1.22-1.61)   1.42 (1.23-1.63)        1.15 (0.99-1.32)          1.16 (1.00-1.34)               1.09 (0.95-1.26)      1.10 (0.95-1.27)      
  ≥ 30                               1.94 (1.48-2.53)   1.99 (1.52-2.60)        1.59 (1.21-2.09)          1.64 (1.25-2.15)               1.45 (1.11-1.91)      1.48 (1.13-1.95)      
  Family history of T2DM (Ref: No)   Yes                1.59 (1.34-1.90)        1.58 (1.33-1.88)          1.46 (1.23-1.74)               1.45 (1.22-1.73)      1.42 (1.19-1.69)      1.41 (1.19-1.68)
  HTN history (Ref: No)              Yes                1.47 (1.29-1.67)        1.47 (1.29-1.67)          1.19 (1.05-1.36)               1.19 (1.05-1.36)      1.19 (1.05-1.36)      1.20 (1.05-1.36)
  Regular exercise (Ref: No)         Yes                1.16 (1.03-1.31)        1.16 (1.03-1.32)          1.15 (1.01-1.30)               1.15 (1.01-1.30)      1.17 (1.03-1.32)      1.16 (1.03-1.32)
  Triglyceride (Ref: \< 120 mg/dL)   120-150                                                              1.32 (1.11-1.59)               1.32 (1.10-1.58)      1.29 (1.08-1.55)      1.29 (1.08-1.55)
  ≥ 150                                                                         1.88 (1.61-2.18)          1.88 (1.62-2.19)               1.77 (1.52-2.06)      1.78 (1.53-2.07)      
  HDL-C (Ref: ≥ 50 mg/dL)            \< 35                                                                1.22 (1.00-1.50)               1.22 (0.99-1.49)      1.22 (1.00-1.50)      1.21 (0.99-1.49)
  35-49                                                                         1.06 (0.91-1.23)          1.06 (0.91-1.23)               1.07 (0.92-1.24)      1.07 (0.92-1.24)      
  FPG (Ref: 90-100 mg/dL)            \< 90                                                                0.49 (0.42-0.56)               0.49 (0.43-0.57)      0.52 (0.45-0.60)      0.53 (0.46-0.61)
  ≥ 100                                                                         2.23 (1.83-2.72)          2.21 (1.81-2.69)               2.13 (1.75-2.60)      2.11 (1.74-2.57)      
  HbA1c (Ref: \< 5.5%)               ≥ 5.5                                                                                                                     2.01 (1.73-2.34)      1.99 (1.71-2.32)
  GPS-18                                                                        1.04 (1.02-1.06)                                         1.03 (1.01-1.05)                            1.03 (1.01-1.06)
  *GPS-18*(*weighted*)                                                          *1.05 (1.03-1.07)*                                       *1.04 (1.02-1.06)*                          *1.03 (1.01-1.05)*
  1\) Discrimination                                                                                                                                                                 
   AUC (95% CI)                                         0.621 (0.603-0.639)     0.628 (0.610-0.646)       0.702 (0.685-0.720)            0.705 (0.688-0.723)   0.724 (0.707-0.740)   0.725 (0.709-0.742)
   *P* value for contrast                               0.033                   0.054                     0.130                                                                      
  2\) Calibration                                                                                                                                                                    
   Hosmer-Lemeshow χ^2^ (*P*)                           10.34 (0.2417)          20.08 (0.01)              7.57 (0.4766)                  6.98 (0.5388)         9.17 (0.3283)         13.24 (0.1038)
  3\) Reclassification                                                                                                                                                               
   IDI, (SE)                                            0.0036 (0.0008)         0.002 (0.0007)            0.0019 (0.0007)                                                            
   *P* value                                            \< 0.001                0.002                     0.005                                                                      
   NRI, (SE)                                            0.0507 (0.0138)         0.0326 (0.0106)           0.0101 (0.0105)                                                            
   *P* value                                            \< 0.001                0.002                     0.336                                                                      

Range of risk alleles scores (GPS-18); 0-36. Model 1 (simple model) adjusted for age, BMI, family history of T2DM, HTN history, regular physical exercise±risk alleles; model 2 (clinical model), adjusted for variables in model 1 plus triglyceride, HDL-cholesterol, FPG±risk alleles; model 3, adjusted for all variables in model 3±risk alleles. Risk classification in NRI analysis: 10%, 20%, 30%. T2DM, type 2 diabetes mellitus; GPS, genetic predisposition score; HDL, high-density lipoprotein; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance index; AUC, area under the curve; IDI, integrated discrimination improvement; NRI, net reclassification improvement.

###### Evaluation of T2DM risk prediction with consideration for genetic predisposition derived from 36 selected SNPs (GPS-36)

![](jkms-30-1101-i005)

  Parameters                                            Model 1: Simple model   Model 2: Clinical model   Model 3: Full clinical model                                               
  ---------------------------------- ------------------ ----------------------- ------------------------- ------------------------------ --------------------- --------------------- ---------------------
  Age                                                   1.03 (1.02-1.04)        1.03 (1.02-1.04)          1.03 (1.02-1.04)               1.03 (1.02-1.04)      1.02 (1.01-1.04)      1.02 (1.01-1.04)
  BMI (Ref: \< 23 kg/m^3^)           23-25              1.09 (0.86-1.39)        1.09 (0.86-1.39)          1.03 (0.81-1.31)               1.03 (0.81-1.32)      1.04 (0.81-1.32)      1.05 (0.82-1.33)
  25-30                              1.32 (1.07-1.62)   1.34 (1.09-1.64)        1.15 (0.94-1.42)          1.16 (0.94-1.43)               1.10 (0.89-1.36)      1.11 (0.90-1.37)      
  ≥ 30                               2.09 (1.43-3.07)   2.21 (1.50-3.23)        1.98 (1.34-2.91)          2.04 (1.39-3.01)               1.74 (1.18-2.56)      1.80 (1.22-2.65)      
  Family history of T2DM (Ref: No)   Yes                1.49 (1.15-1.93)        1.48 (1.14-1.91)          1.33 (1.03-1.73)               1.33 (1.02-1.72)      1.30 (1.00-1.69)      1.31 (1.01-1.70)
  HTN history (Ref: No)              Yes                1.47 (1.22-1.76)        1.47 (1.22-1.77)          1.13 (0.93-1.36)               1.13 (0.93-1.37)      1.12 (0.93-1.36)      1.13 (0.93-1.37)
  Regular exercise (Ref: No)         Yes                1.31 (1.09-1.57)        1.32 (1.10-1.59)          1.28 (1.07-1.54)               1.29 (1.07-1.55)      1.27 (1.06-1.53)      1.28 (1.07-1.54)
  Triglyceride (Ref: \< 120 mg/dL)   120-150                                                              1.35 (1.03-1.76)               1.34 (1.03-1.76)      1.33 (1.02-1.74)      1.33 (1.02-1.74)
  ≥ 150                                                                         2.10 (1.68-2.62)          2.11 (1.69-2.63)               1.98 (1.59-2.48)      2.00 (1.60-2.50)      
  HDL-C (Ref: ≥ 50 mg/dL)            \< 35                                                                0.97 (0.72-1.32)               0.99 (0.73-1.34)      0.96 (0.71-1.29)      0.96 (0.71-1.31)
  35-49                                                                         0.92 (0.74-1.15)          0.93 (0.74-1.16)               0.92 (0.73-1.14)      0.92 (0.74-1.15)      
  FPG (Ref: 90-100 mg/dL)            \< 90                                                                0.52 (0.42-0.64)               0.54 (0.43-0.67)      0.56 (0.45-0.70)      0.58 (0.47-0.72)
  ≥ 100                                                                         3.20 (2.41-4.24)          3.16 (2.38-4.19)               3.09 (2.33-4.10)      3.05 (2.30-4.05)      
  HbA1c (Ref: \< 5.5%)               ≥ 5.5                                                                                                                     2.07 (1.66-2.59)      2.05 (1.64-2.55)
  GPS-36                                                                        1.05 (1.03-1.06)                                         1.03 (1.02-1.05)                            1.04 (1.02-1.07)
  *GPS-36*(*weighted*)                                                          *1.06 (1.03-1.08)*                                       *1.04 (1.02-1.07)*                          *1.03 (1.01-1.05)*
  1\) Discrimination                                                                                                                                                                 
   AUC (95% CI)                                         0.629 (0.604-0.655)     0.643 (0.617-0.669)       0.713 (0.687-0.738)            0.719 (0.694-0.744)   0.735 (0.711-0.760)   0.740 (0.716-0.765)
   *P* value for contrast                               0.047                   0.041                     0.050                                                                      
  2\) Calibration                                                                                                                                                                    
   Hosmer-Lemeshow χ^2^ (*P*)                           8.84 (0.3556)           7.74 (0.4595)             6.65 (0.5750)                  9.66 (0.2898)         14.14 (0.0781)        10.96 (0.2041)
  3\) Reclassification                                                                                                                                                               
   IDI, (SE)                                            0.0086 (0.0018)         0.005 (0.0016)            0.0041 (0.0015)                                                            
   *P* value                                            \< 0.001                0.003                     0.007                                                                      
   NRI, (SE)                                            0.0863 (0.0239)         0.0440 (0.0175)           0.0173 (0.0185)                                                            
   *P* value                                            \< 0.001                0.012                     0.352                                                                      

Range of risk alleles scores (GPS-36); 0-72. Model 1 (simple model) adjusted for age, BMI, family history of T2DM, HTN history, regular physical exercise±risk alleles; model 2 (clinical model), adjusted for variables in model 1 plus triglyceride, HDL-cholesterol, FPG±risk alleles; model 3, adjusted for all variables in model 3±risk alleles. Risk classification in NRI analysis: 10%, 20%, 30%. T2DM, type 2 diabetes mellitus; GPS, genetic predisposition score; HDL, high-density lipoprotein; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance index; AUC, area under the curve; IDI, integrated discrimination improvement; NRI, net reclassification improvement.
